[SCHEDULE 13G/A] Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock SEC Filing

Rhea-AI Filing Summary

Kua Khai Loon reports beneficial ownership of 872,000 shares of Cyclacel Pharmaceuticals, Inc., representing 20.76% of the outstanding common stock. The reported ownership is composed of 218,000 shares of common stock and 218,000 warrants in each of three series (Series A, B and C), each exercisable into common stock, for a total of 872,000 underlying shares. The filing certifies the holdings were not acquired to change or influence control of the issuer. The report includes links to the amended and restated warrant forms as exhibits.

Positive

• Material ownership disclosed: Reporting person transparently reports a 20.76% beneficial stake.
• Clear composition: Ownership breakdown shows 218,000 common shares plus 218,000 Series A, 218,000 Series B and 218,000 Series C warrants.
• Compliance and certification: Filing includes a certification that holdings are not intended to change control and provides exhibits for warrant terms.

Negative

• High ownership concentration: A single beneficial holder controls over 20% of the class, which could increase voting concentration and potential governance influence if warrants are exercised.
• Potential dilution uncertainty: The exercise terms and timing of the three warrant series are not summarized in the filing text, leaving unclear the near-term dilution impact.

Insights

Financial Analyst

TL;DR: A single holder discloses a >20% position through stock plus warrants, a material stake that investors should note for ownership concentration.

The filing shows Kua Khai Loon beneficially owns 872,000 shares or equivalent, equal to 20.76% of common stock, composed of 218,000 shares and three equal tranches of 218,000 warrants. This aggregation creates a meaningful ownership percentage that may affect voting power if warrants are exercised. The statement asserts the position was not taken to change control, and exhibits reference the warrant agreements, which determine exercise terms and timing that could affect dilution and future ownership calculations.

Corporate Governance Expert

TL;DR: Disclosure of a >20% holder is material for governance and board dynamics; warrant terms will determine future governance impact.

The schedule is a clear, compliant disclosure of beneficial ownership under Schedule 13G/A. The filing emphasizes sole voting and dispositive power over all reported shares and notes the holdings include warrants in three series, which are linked as exhibits. Governance implications hinge on whether and when those warrants are exercised and on any contractual limitations in the warrant agreements. The certification clarifies no intent to change control, which is relevant for regulatory and shareholder signaling.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Cyclacel Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

23254L876

(CUSIP Number)

09/01/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23254L876

1

Names of Reporting Persons

Kua Khai Loon

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MALAYSIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 872,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 872,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

872,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

20.76 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 218,000 shares of common stock, (ii) 218,000 series A warrants to purchase shares of common stock, (iii) 218,000 series B warrants to purchase shares of common stock, and (iv) 218,000 series C warrants to purchase shares of common stock (the series A warrants, series B warrants and series C warrants, collectively, the "Warrants")

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cyclacel Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
Item 2.
(a)	Name of person filing: Kua Khai Loon
(b)	Address or principal business office or, if none, residence: NO 28 JALAN EKOFLORA 1/13 TAMAN EKOFLORA JOHOR BAHRU 81100 JOHOR MALAYSIA
(c)	Citizenship: Malaysia
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 23254L876
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 872,000
(b)	Percent of class: 20.76%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 872,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 872,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Kua Khai Loon

Signature:	/s/ Kua Khai Loon
Name/Title:	Kua Khai Loon
Date:	09/01/2025

Exhibit Information

Form of Amended and Restated Series A Common Stock Warrant Form of Amended and Restated Series B Common Stock Warrant Form of Amended and Restated Series C Common Stock Warrant sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-1.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-2.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-3.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-4.htm

FAQ

What stake does Kua Khai Loon report in Cyclacel Pharmaceuticals (CYCCP)?

The filing reports beneficial ownership of 872,000 shares, equal to 20.76% of common stock.

How is the 872,000-share figure composed in the CYCCP filing?

It consists of 218,000 common shares and 218,000 Series A warrants, 218,000 Series B warrants and 218,000 Series C warrants.

Does the filer state an intent to influence control of Cyclacel (CYCCP)?

No; the certification states the securities were not acquired and are not held to change or influence control of the issuer.

Where can I find the warrant terms referenced in the filing?

The filing includes exhibit links to the amended and restated Series A, B and C warrant forms for the specific exercise terms.

What voting and dispositive power does the reporting person claim?

The filer reports sole voting power and sole dispositive power over all 872,000 shares and none shared.